GENERIC LEADERS SUPPORT NOMINEE TO HEAD FDA

NOVEMBER 01, 2006

The nomination of Andrew von Eschenbach, MD, to serve as commissioner of the FDA drew a solid thumbs-up from generic drug industry leaders, who are hopeful that permanent leadership at the agency will result in more focus on cost-saving generic pharmaceuticals.

"As an agency whose mission it is to protect the public health, [the FDA] needs a leader at the helm," Generic Pharmaceutical Association President Kathleen Jaeger said. "The FDA has many critical issues on its plate that impact consumers' ability to obtain safe, effective, and affordable generic medicines, such as establishing an abbreviated approval pathway for generic biopharmaceuticals and ensuring increased funding for the Office of Generic Drugs."




SHARE THIS SHARE THIS
0

Conference Coverage

Check back here regularly for live conference coverage from the American Academy of Pain Medicine and the upcoming American Pharmacists Association Meeting and Expo. 


Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.